Skip to main content
. 2023 May 7;13(5):e1260. doi: 10.1002/ctm2.1260

FIGURE 2.

FIGURE 2

BATF2 is degraded by ubiquitination after translocation to cytoplasm in colorectal cancer (CRC) cells. (A and B) Representative immunohistochemistry (IHC) staining of BATF2 in CRC tissues with high, moderate and low differentiation (A) and the quantification analysis using ImageJ software (B). (C and D) Western blot analysis of BATF2 expression in CCD 841 CoN and HCT116 cells incubated with 10 µM cycloheximide (CHX), a translational inhibitor, for the indicated time (C) and the quantification analysis using ImageJ software (D). (E) Immunofluorescence assay and Western blot analysis of BATF2 expression in CCD 841 CoN and HCT116 cells treated with control or 10 µM MG132, a proteasome inhibitor. Scale bar: 10 µm. (F) Western blot analysis of BATF2 expression in HCT116 cells treated with control or MG132. (G) Co‐immunoprecipitation (co‐IP) analysis of the binding between BATF2 and ubiquitin in CCD 841 CoN and HCT116 cells, taking immunoglobulin G (IgG) as a negative control and total protein as a positive control. 841: CCD 841 CoN; 116: HCT116. Data are expressed as mean ± SD. *** p < .001.